Delayed-onset obsessive-compulsive symptoms after brain infarctions treated with paroxetine

Clinical Neuropharmacology

Volumn 34, Issue 6, 2011, Pages 260-261

  Muneoka, Katsumasa ^a,b   Shirayama, Yukihiko ^c   Kon, Katsushi ^a   Kawabe, Masaharu ^a   Kimura, Sho ^a  

^a Gakuji kai Kimura Hospital   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

Author keywords

brain infarction; middle cerebral artery; obsessive compulsive symptoms; paroxetine; serotonin selective reuptake inhibitor

Indexed keywords

CLOTIAZEPAM; PAROXETINE;

AGED; ANAMNESIS; ARTICLE; BRAIN INFARCTION; CASE REPORT; DRUG DOSE INCREASE; FEMALE; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; SYMPTOMATOLOGY; TREATMENT RESPONSE; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

AGED; BRAIN INFARCTION; FEMALE; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PAROXETINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 82055165688     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3182329670     Document Type: Article

References (11)

1. Beckson M, Cummings JL. Neuropsychiatric aspects of stroke. Int J Psychiatry Med 1991;21:1-15.
2. Benejam B, Sahuquillo J, Poca MA, et al. Quality of life and neurobehavioral changes in survivors of malignant middle cerebral artery infarction. J Neurol 2009;256:1126-1133.
3. Breier JI, Castillo EM, Boake C, et al. Spatiotemporal patterns of language-specific brain activity in patients with chronic aphasia after stroke using magnetoencephalography. Neuroimage 2004;23:1308-1316. (Pubitemid 40260354)
4. Goto A, Okuda S, Ito S, et al. Locomotion outcome in hemiplegic patients with middle cerebral artery infarction: the difference between right-and left-sided lesions. J Stroke Cerebrovasc Dis 2009;18:60-67.
5. Matsui T, Saxena S, Kawabe J, et al. Secondary obsessive-compulsive disorder related to diaschisis after pontine infarction, successfully treated with paroxetine. Psychiatry Clin Neurosci 2007;61: 186-189. (Pubitemid 46365265)
6. Gerdelat-Mas A, Loubinoux I, Tombari D, et al. Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects. Neuroimage 2005;27:314-322. (Pubitemid 41074834)
7. Loubinoux I, Tombari D, Pariente J, et al. Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer. Neuroimage 2005;27:299-313. (Pubitemid 41074833)
8. Péran P, Démonet JF, Cardebat D. Paroxetine-induced modulation of cortical activity supporting language representations of action. Psychopharmacology (Berl) 2008;195:487-496. (Pubitemid 350160492)
9. de Boissezon X, Peran P, de Boysson C, et al. Pharmacotherapy of aphasia: myth or reality? Brain Lang 2007;102:114-125. (Pubitemid 46809752)
10. Menzies L, Chamberlain SR, Laird AR, et al. Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited. Neurosci Biobehav Rev 2008;32:525-549. (Pubitemid 351173336)
11. Saxena S, Brody AL, Ho ML, et al. Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. Arch Gen Psychiatry 2002;59:250-261. (Pubitemid 34212502)